BR112014021173A2 - Teste diagnóstico da resistência à azacitidina - Google Patents

Teste diagnóstico da resistência à azacitidina

Info

Publication number
BR112014021173A2
BR112014021173A2 BR112014021173A BR112014021173A BR112014021173A2 BR 112014021173 A2 BR112014021173 A2 BR 112014021173A2 BR 112014021173 A BR112014021173 A BR 112014021173A BR 112014021173 A BR112014021173 A BR 112014021173A BR 112014021173 A2 BR112014021173 A2 BR 112014021173A2
Authority
BR
Brazil
Prior art keywords
azacitidine
patient
biological fluid
bcl2l10
protein
Prior art date
Application number
BR112014021173A
Other languages
English (en)
Portuguese (pt)
Inventor
Auberger Patrick
Robert Guillaume
Cluzeau Thomas
Luciano Frédéric
Original Assignee
Inst Nat Sante Rech Med
Univ Nice Sophia Antipolis
Centre Hospitalier Univ De Nice
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Nice Sophia Antipolis, Centre Hospitalier Univ De Nice filed Critical Inst Nat Sante Rech Med
Publication of BR112014021173A2 publication Critical patent/BR112014021173A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
BR112014021173A 2012-02-28 2013-02-28 Teste diagnóstico da resistência à azacitidina BR112014021173A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200584A FR2987446B1 (fr) 2012-02-28 2012-02-28 Test diagnostic de la resistance a l'azacitidine
PCT/FR2013/000055 WO2013128089A1 (fr) 2012-02-28 2013-02-28 Test diagnostic de la résistance à l'azacitidine

Publications (1)

Publication Number Publication Date
BR112014021173A2 true BR112014021173A2 (pt) 2017-08-22

Family

ID=48083449

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021173A BR112014021173A2 (pt) 2012-02-28 2013-02-28 Teste diagnóstico da resistência à azacitidina

Country Status (11)

Country Link
US (1) US20150094217A1 (enExample)
EP (1) EP2820417A1 (enExample)
JP (1) JP6273552B2 (enExample)
CN (1) CN104321649A (enExample)
AU (1) AU2013224832A1 (enExample)
BR (1) BR112014021173A2 (enExample)
CA (1) CA2865684A1 (enExample)
FR (1) FR2987446B1 (enExample)
IL (1) IL234332A0 (enExample)
IN (1) IN2014MN01795A (enExample)
WO (1) WO2013128089A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2924125B1 (en) * 2014-03-27 2017-06-14 Palacky University, Olomouc Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance
FR3048698B1 (fr) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
WO2019077080A1 (en) * 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 ASSESSING THE RISK OF METASTATIC RECHUTE IN PATIENTS WITH BREAST CANCER
CN114874987A (zh) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） 一种骨髓异常增生综合征耐药细胞模型及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078100A1 (ja) 2004-02-13 2005-08-25 Bml, Inc. 薬剤耐性を獲得した癌細胞の検出方法
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
CN101632643A (zh) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 阿扎胞苷冻干粉针制剂及其制备方法
JP5190477B2 (ja) * 2010-02-22 2013-04-24 譲治 稲澤 カンプトテシン類の制癌剤に対する薬剤耐性を獲得した肺癌細胞の検出方法
EP2576825B1 (en) * 2010-05-27 2017-11-08 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for assessing endometrium receptivity of a patient

Also Published As

Publication number Publication date
FR2987446B1 (fr) 2016-01-01
JP2015513369A (ja) 2015-05-11
AU2013224832A1 (en) 2014-10-16
EP2820417A1 (fr) 2015-01-07
FR2987446A1 (fr) 2013-08-30
IN2014MN01795A (enExample) 2015-07-03
WO2013128089A1 (fr) 2013-09-06
JP6273552B2 (ja) 2018-02-07
AU2013224832A8 (en) 2014-11-13
US20150094217A1 (en) 2015-04-02
IL234332A0 (en) 2014-10-30
CA2865684A1 (fr) 2013-09-06
CN104321649A (zh) 2015-01-28

Similar Documents

Publication Publication Date Title
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112015026248A2 (pt) dispositivo de coleta de fluido biológico e sistema de separação e teste de fluido biológico
MX364886B (es) Lente oftálmica con sistema microfluídico.
BR112014016313A2 (pt) medições precisas de analito para tira de teste eletroquímico com base em característica(s) física(s) detectada(s) da amostra contendo o analito e parâmetros de biossensores derivados
MX378788B (es) Kits y ensayos de diagnóstico para la detección del receptor 1 de folato.
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
IN2014MN02060A (enExample)
BR112015026156A2 (pt) dispositivo para separação de fluido biológico e sistema de teste e separação de fluido biológico
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
BR112014032274A2 (pt) tira de teste analítico com câmaras receptoras de amostra capilar separadas por uma barreira física de isolamento
IL236819A0 (en) Image analysis and measurement of biological samples
BR112014031835A2 (pt) tira de teste analítico de base eletroquímica com câmaras receptoras de amostra cruzadas
WO2014124339A3 (en) Use of translational profiling to identify target molecules for therapeutic treatment
MA38042B2 (fr) Méthylglyoxal en tant que marqueur du cancer
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
BR112015015341A2 (pt) composições para permeabilização de células sanguíneas fixadas e usos das mesmas
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
GB2515713A (en) Methods, packaging and apparatus for collection of biological samples
GB201102693D0 (en) Method for identifying neonates at risk for necrotizing enterocolitis
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
IN2014MN01795A (enExample)
BR112016026694A2 (pt) teste de diagnóstico e tratamento/prevenção da doença de alzheimer
AR085164A1 (es) Metodos para el analisis de la placa
BR112017027304A2 (pt) método para o diagnóstico de doença de farber

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]